Nancy Wysenski Biography and Net Worth

Director of Alkermes


Ms. Wysenski most recently served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Inc. from December 2009 through June 2012. Prior to joining Vertex, she held the position of Chief Operating Officer of Endo Pharmaceuticals plc (“Endo”), where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves on the Board of Directors of Cytokinetics, Inc. She was previously on the Boards of Directors of Provention Bio, Inc., Dova Pharmaceuticals Inc., Reata Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. She is a founder of the Research Triangle Park Chapter of the Healthcare Businesswomen’s Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen’s Association.

What is Nancy Wysenski's net worth?

The estimated net worth of Nancy Wysenski is at least $390,659.72 as of May 9th, 2023. Ms. Wysenski owns 15,829 shares of Alkermes stock worth more than $390,660 as of April 28th. This net worth evaluation does not reflect any other assets that Ms. Wysenski may own. Learn More about Nancy Wysenski's net worth.

How do I contact Nancy Wysenski?

The corporate mailing address for Ms. Wysenski and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Nancy Wysenski's contact information.

Has Nancy Wysenski been buying or selling shares of Alkermes?

Nancy Wysenski has not been actively trading shares of Alkermes over the course of the past ninety days. Most recently, Nancy Wysenski sold 41,250 shares of the business's stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $31.24, for a transaction totalling $1,288,650.00. Following the completion of the sale, the director now directly owns 15,829 shares of the company's stock, valued at $494,497.96. Learn More on Nancy Wysenski's trading history.

Who are Alkermes' active insiders?

Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.

Are insiders buying or selling shares of Alkermes?

During the last year, insiders at the sold shares 4 times. They sold a total of 81,601 shares worth more than $2,454,554.32. The most recent insider tranaction occured on March, 18th when SVP Christian Todd Nichols sold 10,417 shares worth more than $292,717.70. Insiders at Alkermes own 4.8% of the company. Learn More about insider trades at Alkermes.

Information on this page was last updated on 3/18/2024.

Nancy Wysenski Insider Trading History at Alkermes

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2023Sell41,250$31.24$1,288,650.0015,829View SEC Filing Icon  
2/24/2020Buy6,940$19.93$138,314.20
2/21/2019Buy3,857$33.09$127,628.13View SEC Filing Icon  
See Full Table

Nancy Wysenski Buying and Selling Activity at Alkermes

This chart shows Nancy Wysenski's buying and selling at Alkermes by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alkermes Company Overview

Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $24.68
Low: $24.30
High: $24.80

50 Day Range

MA: $27.30
Low: $23.76
High: $32.18

2 Week Range

Now: $24.68
Low: $22.01
High: $33.71

Volume

1,016,741 shs

Average Volume

1,805,169 shs

Market Capitalization

$4.18 billion

P/E Ratio

11.92

Dividend Yield

N/A

Beta

0.55